Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease
- 1Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK
- 2Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
- Correspondence to Dr Alexander Charles Ford, Leeds Gastroenterology Institute, Room 125, 4th Floor, Bexley Wing, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK;
- Accepted 3 September 2012
- Published Online First 27 September 2012
We read the article by Sands et al1 with interest. The efficacy of granulocyte/monocyte apheresis (GMA) in inflammatory bowel disease (IBD) is controversial, with previous studies mainly conducted in Japan, involving small numbers of patients, often without sham controls.2–4 The authors should, therefore, be congratulated for performing a large, randomised, double-blind, sham-controlled study of GMA in moderate to severely active Crohn's disease in a Western population.